0 CHECKOUT

Macular Edema - Pipeline Review, H1 2015

  • ID: 3280636
  • May 2015
  • 72 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Allergan, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Promedior, Inc.
  • MORE

Macular Edema - Pipeline Review, H1 2015

Summary

This, ‘Macular Edema - Pipeline Review, H1 2015’, provides an overview of the Macular Edema’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Macular Edema and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Promedior, Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Macular Edema Overview
Therapeutics Development
Pipeline Products for Macular Edema - Overview
Pipeline Products for Macular Edema - Comparative Analysis
Macular Edema - Therapeutics under Development by Companies
Macular Edema - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Macular Edema - Products under Development by Companies
Macular Edema - Companies Involved in Therapeutics Development
Allergan, Inc.
Clearside BioMedical, Inc.
F. Hoffmann-La Roche Ltd.
Pfizer Inc.
Promedior, Inc.
Regeneron Pharmaceuticals, Inc.
Taiwan Liposome Company, Ltd.
Macular Edema - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(triamcinolone acetonide + aflibercept) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aflibercept (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
beclomethasone dipropionate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
celecoxib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dexamethasone acetate SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRM-167 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ranibizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ranibizumab SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
triamcinolone acetonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Macular Edema - Recent Pipeline Updates
Macular Edema - Dormant Projects
Macular Edema - Discontinued Products
Macular Edema - Product Development Milestones
Featured News & Press Releases
Mar 02, 2015: Clearside Biomedical Initiates Phase 2 Clinical Trial to Evaluate Reducing Treatment Visits While Improving Outcomes in Macular Edema Associated with Retinal Vein Occlusion
Jan 23, 2015: EYLEA(aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central or Branch Retinal Vein Occlusion in the European Union
Jan 06, 2015: Government Subsidy of NT$17.6M granted for TLC’s Ophthalmology Drug Phase I/II trial
Oct 06, 2014: EYLEA (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO)
Sep 04, 2014: Regeneron Announces Submission of Application for EYLEA (aflibercept) Injection in Japan for Macular Edema Following Branch Retinal Vein Occlusion
Feb 25, 2014: NICE gives green light to treatment for macular oedema in final guidance
Feb 24, 2014: Regeneron Announces FDA Acceptance of EYLEA (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion
Dec 27, 2013: NICE gives green light to treatment for macular oedema in final draft guidance
Dec 23, 2013: TLC receives FDA IND approval for Sustained Release Macular Disease Drug
Nov 22, 2013: EYLEA Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Macular Edema, H1 2015
Number of Products under Development for Macular Edema - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Macular Edema - Pipeline by Allergan, Inc., H1 2015
Macular Edema - Pipeline by Clearside BioMedical, Inc., H1 2015
Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Macular Edema - Pipeline by Pfizer Inc., H1 2015
Macular Edema - Pipeline by Promedior, Inc., H1 2015
Macular Edema - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015
Macular Edema - Pipeline by Taiwan Liposome Company, Ltd., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Macular Edema Therapeutics - Recent Pipeline Updates, H1 2015
Macular Edema - Dormant Projects, H1 2015
Macular Edema - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Macular Edema, H1 2015
Number of Products under Development for Macular Edema - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

- Allergan, Inc.
- Clearside BioMedical, Inc.
- F. Hoffmann-La Roche Ltd.
- Pfizer Inc.
- Promedior, Inc.
- Regeneron Pharmaceuticals, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • AB Sciex
  • Eli Lilly and Company
  • B. Braun Melsungen AG
  • Astellas Pharma, Inc.
  • Hologic Inc.
  • Merck & Co., Inc.